Effects of demographics on the antihypertensive efficacy of triple therapy with amlodipine, valsartan, and hydrochlorothiazide for moderate to severe hypertension

Abstract Objective: To compare the antihypertensive efficacy and safety of once-daily triple therapy with amlodipine (Aml) 10 mg, valsartan (Val) 320 mg, and hydrochlorothiazide (HCTZ) 25 mg versus dual-therapy combinations of these components in patients with moderate to severe hypertension. Resear...

Full description

Saved in:
Bibliographic Details
Published in:Current medical research and opinion 2013-08, Vol.29 (8), p.901-910
Main Authors: Calhoun, David A., Lacourcière, Yves, Crikelair, Nora, Jia, Yan, Glazer, Robert D.
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Aged, 80 and over
Amlodipine
Amlodipine - administration & dosage
Amlodipine - adverse effects
Amlodipine - therapeutic use
Antihypertensive Agents - administration & dosage
Antihypertensive Agents - adverse effects
Antihypertensive Agents - therapeutic use
Arterial hypertension. Arterial hypotension
Biological and medical sciences
Blood and lymphatic vessels
Blood Pressure
Cardiology. Vascular system
Demography
Drug Therapy, Combination
Female
Humans
Hydrochlorothiazide
Hydrochlorothiazide - administration & dosage
Hydrochlorothiazide - adverse effects
Hydrochlorothiazide - therapeutic use
Hypertension
Hypertension - drug therapy
Hypertension - physiopathology
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Severity of Illness Index
Tetrazoles - administration & dosage
Tetrazoles - adverse effects
Tetrazoles - therapeutic use
Triple therapy
Valine - administration & dosage
Valine - adverse effects
Valine - analogs & derivatives
Valine - therapeutic use
Valsartan
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Objective: To compare the antihypertensive efficacy and safety of once-daily triple therapy with amlodipine (Aml) 10 mg, valsartan (Val) 320 mg, and hydrochlorothiazide (HCTZ) 25 mg versus dual-therapy combinations of these components in patients with moderate to severe hypertension. Research design: Subgroup analysis of a multinational, randomized, double-blind, parallel-group, active-controlled trial. Methods: After antihypertensive washout and a placebo run-in of up to 4 weeks, 2271 patients were randomly allocated in a 1:1:1:1 ratio to receive Aml/Val/HCTZ triple therapy or dual therapy with Val/HCTZ, Aml/Val, or Aml/HCTZ for 8 weeks. Forced titration to the full dose was done over the first 2 weeks of treatment. Efficacy and safety parameters were determined by age group (
ISSN:0300-7995
1473-4877
DOI:10.1185/03007995.2013.803057